Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
S&P/ASX 200 (ASX:XJO) managed a 0.2% gain on Friday, overcoming weakness in healthcare. Karoon Energy Ltd (ASX:KAR) share price rose 4.2%.
The S&P/ASX 200 (ASX: XJO) finished broadly flat on Tuesday as Woolworths (ASX:WOW) and Mesoblast (ASX:MSB) shares were in the news.
The Mesoblast Limited (ASX:MSB) share price is being crunched. It’s down 16% after giving an update about its Novartis (SWX:NOVN) agreement.
The S&P/ASX 200 (ASX:XJO) continued its positive run on Wednesday as Magellan (ASX:MFG) and Telstra (ASX:TLS) shares made headlines.
The S&P/ASX 200 (ASX: XJO) gained another 0.3% to begin the week as Woodside (ASX:WPL) and Telstra (ASX:TLS) shares made headlines.
Shares in Mesoblast Limited (ASX: MSB) have taken a 21% dive this week following the release of its FY21 results. Here are the details.
The Mesoblast Limited (ASX:MSB) share price is under the spotlight right now on its FY21 fourth quarter.
Mesoblast Limited (ASX: MSB) shares have had a horrid twelve months, falling by 40%. Can this new lower back pain drug lift Mesoblast shares?
The S&P/ASX 200 (ASX: XJO) delivered another strong day on Friday. Boral (ASX:BLD) and Seven (ASX:SVW) shares are making headlines.
